Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04868123
Other study ID # Pro2020003234
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 22, 2022
Est. completion date April 30, 2024

Study information

Verified date August 2023
Source Rutgers, The State University of New Jersey
Contact David M Kietrys, PhD
Phone 856-566-7186
Email kietrydm@shp.rutgers.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to explore the effects of transcutaneous nerve stimulation (TENS) and mindfulness meditation in persons living with HIV (PLHIV) and painful neuropathy in the feet.


Description:

The overall goal of this study is to conduct an interventional pilot trial of mindfulness meditation and transcutaneous nerve stimulation (TENS) to mitigate the symptoms and improved function in persons living with HIV (PLHIV) and painful neuropathy in the feet. . The investigators aim to determine the feasibility and effects of (1) mindfulness meditation or (2) transcutaneous nerve stimulation (TENS) on clinical and functional outcomes in participants with HIV-associated painful distal sensory polyneuropathy in the feet. This aim will be achieved with a randomized control pilot trial with 3 groups: TENS group, Mindfulness Mediation Group, and Usual Treatment (Control) group. The interventions will be performed at home over a period of 6 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date April 30, 2024
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - diagnosis of HIV infection currently treated with antiretroviral therapy (ART) - cluster of differentiation 4 cell (CD4 cell) count of at least 200 cells/mm3 - 18-64 years of age - able to read and write in English - means to travel to a study site - presence of peripheral neuropathy symptoms in feet - average daily self-reported pain in the feet of at least 3/10 on a 0-10 numerical pain scale - pain in the feet present for at least the past 3 months - no changes in medications used to manage pain in the past 4 weeks - no use of TENS or mindfulness meditation in the prior 6 months - availability of a mobile phone to receive text messages over the course of the intervention period Exclusion Criteria: - current opportunistic infection(s) - cluster of differentiation 4 cell (CD4 cell) count <200 cells/mm3 - dementia - uncontrolled psychiatric disorder - wounds or sores on the feet - musculoskeletal or neurological conditions (other than distal sensory neuropathy) that may affect gait - pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcutaneous Nerve Stimulation (TENS)
Transcutaneous nerve stimulation (TENS) is a simple home base treatment to manage pain. It involves electrical current applied to the skin through self-adhering electrodes, using a TENS3000 device (TENSPros.com).
Behavioral:
Mindfulness Meditation
Mindfulness mediation is a guided mediation process to improve awareness of being present in the moment.

Locations

Country Name City State
United States Rutgers Physical Therapy Program Blackwood New Jersey
United States Rutgers Physical Therapy Program Newark New Jersey

Sponsors (2)

Lead Sponsor Collaborator
Rutgers University Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Pain Intensity at 7 weeks Responses to questions on the Brief Pain Inventory Pain Intensity subscale used to generate pain intensity score. Minimum score=0; maximum score=10; higher score=worse outcome. Week 0 and Week 7
Primary Change from Baseline Pain Interference at 7 weeks Responses to questions on the Brief Pain Inventory Pain Interference subscale used to generate pain interference score. Minimum score=0; maximum score=10; higher score=worse outcome. Week 0 and Week 7
Secondary Change from Baseline Pain Pressure Threshold at 7 weeks Pain pressure threshold (expressed in pounds or kilograms of force) at lower extremity landmarks via use of a digital algometer. Week 0 and Week 7
Secondary Change from Baseline Gait Characteristics at 7 weeks Temporal and spatial characteristics of gait (walking velocity, step length, step time, stride width, cadence, foot-fall area) as captured with a ZENO instrumented walkway Week 0 and Week 7
Secondary Change from Baseline Walking Endurance at 7 weeks Walking endurance as measured with the 6-Minute Walk test (distance walked over span of 6 minutes). Week 0 and Week 7
Secondary Change in Baseline Physical Performance at 7 weeks Physical performance score generated via the Short Physical Performance Battery. (SPPB). SPPB procedures generate a total score reflective of physical performance. Minimum score=0; maximum score=12; lower score=worse outcome. Week 0 and Week 7
Secondary Change from Baseline Whole Body Strength at 7 weeks Mid-thigh pull test will be used to generate a score expressed as force in pounds or kilograms that is reflective of whole body strength. Week 0 and Week 7
Secondary Change from Baseline Physical Activity at 7 weeks Physical activity characteristics: (1) over a span of 5 days captured via a wrist-band style Actigraph activity monitor, and (2) self-reported physical activity over past 7 days using the International Physical Activity Questionnaire - Short Form Week 0 and Week 7
Secondary Change from Baseline Mental Quality of Life (QOL) at 7 weeks Mental Health Summary Score generated via responses on the Medical Outcomes Study HIV Health Survey (MOS-HIV). Minimum score=0; maximum score=100; lower score=worse outcome. Week 0 and Week 7
Secondary Change from Baseline Physical Quality of Life (QOL) at 7 weeks Physical Health Summary Score generated via responses on the Medical Outcomes Study HIV Health Survey (MOS-HIV). Minimum score=0; maximum score=100; lower score=worse outcome. Week 0 and Week 7
Secondary Change from Baseline Depression at 7 weeks Self-reported depression as determined by the depression subscale of the Hospital Depression and Anxiety Scale. Minimum score=0; maximum score=21; higher score=worse outcome. Week 0 and Week 7
Secondary Change from Baseline Anxiety at 7 weeks Self-reported anxiety as determined by the anxiety subscale of the Hospital Depression and Anxiety Scale. Minimum score=0; maximum score=21; higher score=worse outcome. Week 0 and Week 7
Secondary Change from Baseline Catastrophizing Behaviors at 7 weeks Self-reported catastrophizing behaviors using with the Pain Catastrophizing Scale. Minimum score=0; maximum score=52; higher score=worse outcome. Week 0 and Week 7
Secondary Change from Baseline Resilience behaviors at 7 weeks Self-reported resilience using the 6-item Brief Resilience Scale. Minimum score=1; maximum score=5; lower score=worse outcome. Week 0 and Week 7
Secondary Change from Baseline Pain Medication Use at 7 weeks Self-report of use of pain medication base on responses to a study-specific questionnaire Week 0 and Week 7
Secondary Satisfaction with Study Experiences Self-reported satisfaction with the study parameters and study experiences using a study-specific questionnaire week 7
Secondary Adherence to Home-based Treatment (TENS and Mindfulness Meditation groups) Tracking of adherence to home based intervention (number of sessions per week completed and total number of sessions completed over 6 weeks) via direct communication with participants week 6
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2